Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL29354628 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL28281831 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HPGDMAPTGLAACHE | |
| Phenazine SCHEMBL28557583 | 0.88 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPTGLAACHE | |
| Anthracene SCHEMBL28457231 | 0.88 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPTGLAACHE | |
| Anthracene SCHEMBL28211461 | 0.88 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPTGLAACHE | |
| Acridine SCHEMBL27413186 | 0.87 | CYP1A2 (0.56) | ALDH1A1HPGDMAPTGLAACHE | |
| Naphthalene SCHEMBL2123892 | 0.83 | ALDH1A1 (0.65) | ALDH1A1FKBP5CYP2A6 | |
| Naphthalene SCHEMBL338629 | 0.83 | ALDH1A1 (0.65) | ALDH1A1FKBP5CYP2A6 | |
| Naphthalene SCHEMBL27481708 | 0.81 | ALDH1A1 (0.62) | ALDH1A1FKBP5CYP2A6 | |
| Cinnoline SCHEMBL10732584 | 0.80 | ALDH1A1 (0.45) | ALDH1A1HPGDMAPTGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069470-A | Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis | 杨宁荪 | 2018-12-21 | — | — | CN | claimed |
| CN-108440565-A | A kind of luxuriant receptor of acridine imidazoles ring of naphthalene nucleus bridging and preparation method thereof and the identification application to iron ion and dihydrogen phosphate ions | 福州大学 | 2018-08-24 | — | — | CN | claimed |
| WO-2023202686-A1 | COMPOSITION AND METHOD FOR INHIBITING XANTHINE DEHYDROGENASE (XDH) | 上海舶望制药有限公司 | 2023-10-26 | — | — | WO | disclosed |
| CN-114525280-A | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-110461876-A | For exhausting the composition and method of CD137+ cell | MAGENTA THERAPEUTICS INC | 2019-11-15 | — | — | CN | disclosed |
| CN-109661400-A | Compositions and methods for depleting CD117+ cells | 美真达治疗公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-109641051-A | For exhausting the composition and method of cell | 美真达治疗公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-109069470-A | Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis | 杨宁荪 | 2018-12-21 | — | — | CN | disclosed |
| CN-108602849-A | For by RNA nanotechnologies by the RNA ligand presen-tation allochthons of therapeutic agent specific delivery to cell | 俄亥俄州国家创新基金会 | 2018-09-28 | — | — | CN | disclosed |
| CN-1701063-A | Therapeutic acridone and acridine compounds | CANCER REC TECH LTD (GB) | 2005-11-23 | — | — | CN | disclosed |
| CN-1652772-A | (+) -2- [ 1- (3-ethoxy-4-methoxyphenyl) -2-methylsulfonylethyl ] -4-acetylaminoisoindoline-1, 3-dione, methods of use, and compositions thereof | CELGENE CORP (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| CN-1568188-A | Nociceptin analogs | EURO CELTIQUE SA (LU) | 2005-01-19 | — | — | CN | disclosed |
| CN-1561211-A | Nociceptin analogs | EURO CELTIQUE SA (LU) | 2005-01-05 | — | — | CN | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| CN-1516584-A | Spiropyrazole compounds | ŷ�����ǹɷ�����˾ | 2004-07-28 | — | — | CN | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002079380-A2 | DISRUPTIONS IN GABA RECEPTOR RH02 SUBUNIT, METHODS ADN USES THEREOF | DELTAGEN, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CCNK, TERT, CCNA1 | ALDH1A1 99/4885HPGD 709/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.